Skip to main content

Olema Oncology, Inc 8-K, filed Nov 10, 2026

Olema Oncology, Inc. (OLMA)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Olema Oncology, Inc filed this 8-K on November 10, 2026.

Olema Pharmaceuticals reported a $73.6 million net loss for the quarter ended September 30, 2026 and held $413.8 million in cash, cash equivalents, and marketable securities. It remains on track for OPERA-01 top-line data in the first quarter of 2027. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits